These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28428277)

  • 1. Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.
    Safonov A; Jiang T; Bianchini G; Győrffy B; Karn T; Hatzis C; Pusztai L
    Cancer Res; 2017 Jun; 77(12):3317-3324. PubMed ID: 28428277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
    Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
    Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
    Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
    Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
    Massink MP; Kooi IE; van Mil SE; Jordanova ES; Ameziane N; Dorsman JC; van Beek DM; van der Voorn JP; Sie D; Ylstra B; van Deurzen CH; Martens JW; Smid M; Sieuwerts AM; de Weerd V; Foekens JA; van den Ouweland AM; van Dyk E; Nederlof PM; Waisfisz Q; Meijers-Heijboer H
    Mol Oncol; 2015 Apr; 9(4):877-88. PubMed ID: 25616998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
    Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
    Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
    Karn T; Pusztai L; Ruckhäberle E; Liedtke C; Müller V; Schmidt M; Metzler D; Wang J; Coombes KR; Gätje R; Hanker L; Solbach C; Ahr A; Holtrich U; Rody A; Kaufmann M
    Eur J Cancer; 2012 Jan; 48(1):12-23. PubMed ID: 21741824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
    Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
    Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
    Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
    Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
    O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
    Abba MC; Gong T; Lu Y; Lee J; Zhong Y; Lacunza E; Butti M; Takata Y; Gaddis S; Shen J; Estecio MR; Sahin AA; Aldaz CM
    Cancer Res; 2015 Sep; 75(18):3980-90. PubMed ID: 26249178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.